Source comparison
Tesamorelin + Ipamorelin Blend: Protocol Comparison
The table below compares research protocols using different approaches to growth hormone modulation, including the tesamorelin + ipamorelin blend, single-agent protocols, and alternative peptide combinations. Tesamorelin + Ipamorelin Blend Dual-pathway: GHRH r
This comparison does not assign a generated winner or score.
- The table below compares research protocols using different approaches to growth hormone modulation, including the tesamorelin + ipamorelin blend, single-agent protocols, and alternative peptide combinations.
- Tesamorelin + Ipamorelin Blend
- Dual-pathway: GHRH receptor agonism + selective ghrelin receptor agonism
- 1mg tesamorelin + 200–300mcg ipamorelin, pre-sleep, once daily
- Synchronized pulsatile release, 1.8–2.3× baseline amplitude, preserves circadian pattern
- Requires reconstitution, refrigerated storage, subcutaneous injection; synergy reduces per-compound dose requirements
- Optimal for physiological GH optimization within homeostatic feedback loops; most research-friendly profile
- Tesamorelin Monotherapy
- GHRH receptor agonism only
- 2mg daily subcutaneous injection
- Moderate amplitude increase, dependent on endogenous ghrelin tone
- FDA-approved for HIV lipodystrophy; well-characterized safety profile; limited lean mass effects without GHS co-administration
- Effective for VAT reduction research; less robust growth hormone response than dual-pathway protocols
- Ipamorelin Monotherapy
- Selective ghrelin receptor agonism
- 200–300mcg 2–3× daily
- Brief pulses, amplitude limited by available GHRH and somatotroph secretory capacity
- Requires multiple daily doses; efficacy decreases without concurrent GHRH activity
- Suitable for appetite-neutral GH stimulation; suboptimal as standalone due to single-pathway limitation
- CJC-1295 + Ipamorelin
- Extended GHRH analog + ghrelin receptor agonism
- 500–1000mcg CJC-1295 weekly + 200–300mcg ipamorelin daily
- Prolonged GHRH activity (7–14 days) + pulsatile GHS stimulation
- CJC-1295 DAC variant causes sustained GH elevation; NO DAC variant mimics tesamorelin kinetics more closely
- DAC formulation disrupts pulsatility; NO DAC formulation offers similar profile to tesamorelin but with different receptor kinetics
- MK-677 (Ibutamoren) Monotherapy
- Oral ghrelin receptor agonist
- 10–25mg daily oral administration
- Continuous ghrelin receptor stimulation, blunted pulsatility over time
- Oral bioavailability advantage; causes significant appetite increase and potential insulin resistance with chronic use
- Not recommended for body composition research due to appetite stimulation and receptor desensitization; useful for long-term GH/IGF-1 elevation studies
- Sermorelin + GHRP-6
- GHRH analog + non-selective GHS
- 200–300mcg each, 2–3× daily
- Dual-pathway stimulation with strong appetite and cortisol effects from GHRP-6
- GHRP-6 increases cortisol and prolactin; appetite stimulation complicates body composition protocols
- Effective GH stimulation but side-effect profile limits research applicability compared to tesamorelin + ipamorelin